BG Medicine Inc. signed a deal with Corgenix Medical Corp. (OTC:CONX) for the manufacture of its BGM Galectin-3 diagnostic products, as BGM seeks Food & Drug Administration clearance for the heart failure biomarker.
Denver-based Corgenix makes specialized diagnostic kits for immunological disorders, vascular diseases and bone and joint disorders. Waltham, Mass.-based BGM develops molecular diagnostic products to predict patient response to drugs.
The companies said the deal calls for Corgenix to make the biomarker, which tests for the presence of galectin-3, part of a family of proteins involved in organ fibrosis. Corgenix will make a version of the test in an enzyme-linked immunosorbent assay microtiter format. The ELISA format allows researchers to detect the presence of an antibody or an antigen in a sample.